JP2014503172A5 - - Google Patents

Download PDF

Info

Publication number
JP2014503172A5
JP2014503172A5 JP2012535995A JP2012535995A JP2014503172A5 JP 2014503172 A5 JP2014503172 A5 JP 2014503172A5 JP 2012535995 A JP2012535995 A JP 2012535995A JP 2012535995 A JP2012535995 A JP 2012535995A JP 2014503172 A5 JP2014503172 A5 JP 2014503172A5
Authority
JP
Japan
Prior art keywords
polypeptide
amino acid
seq
acid sequence
item
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012535995A
Other languages
English (en)
Japanese (ja)
Other versions
JP5960055B2 (ja
JP2014503172A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2010/054865 external-priority patent/WO2011051893A1/en
Publication of JP2014503172A publication Critical patent/JP2014503172A/ja
Publication of JP2014503172A5 publication Critical patent/JP2014503172A5/ja
Application granted granted Critical
Publication of JP5960055B2 publication Critical patent/JP5960055B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012535995A 2009-10-27 2010-10-27 改変髄膜炎菌ｆＨＢＰポリペプチド Expired - Fee Related JP5960055B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27997709P 2009-10-27 2009-10-27
US61/279,977 2009-10-27
PCT/IB2010/054865 WO2011051893A1 (en) 2009-10-27 2010-10-27 Modified meningococcal fhbp polypeptides

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015205429A Division JP2016040302A (ja) 2009-10-27 2015-10-19 改変髄膜炎菌ｆＨＢＰポリペプチド

Publications (3)

Publication Number Publication Date
JP2014503172A JP2014503172A (ja) 2014-02-13
JP2014503172A5 true JP2014503172A5 (enExample) 2014-04-03
JP5960055B2 JP5960055B2 (ja) 2016-08-02

Family

ID=43431124

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012535995A Expired - Fee Related JP5960055B2 (ja) 2009-10-27 2010-10-27 改変髄膜炎菌ｆＨＢＰポリペプチド
JP2015205429A Pending JP2016040302A (ja) 2009-10-27 2015-10-19 改変髄膜炎菌ｆＨＢＰポリペプチド

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015205429A Pending JP2016040302A (ja) 2009-10-27 2015-10-19 改変髄膜炎菌ｆＨＢＰポリペプチド

Country Status (9)

Country Link
US (2) US20130022633A1 (enExample)
EP (1) EP2493499A1 (enExample)
JP (2) JP5960055B2 (enExample)
CN (1) CN102917730A (enExample)
AU (1) AU2010310985B2 (enExample)
BR (1) BR112012010531A2 (enExample)
CA (1) CA2779816A1 (enExample)
MX (1) MX2012004850A (enExample)
WO (1) WO2011051893A1 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
CA2756522C (en) 2009-03-24 2018-06-26 Novartis Ag Adjuvanting meningococcal factor h binding protein
JP2013521326A (ja) * 2010-03-10 2013-06-10 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 免疫原性組成物
BR122021020829B8 (pt) * 2010-03-30 2022-12-27 Children´S Hospital & Res Center At Oakland Proteína de ligação ao fator h de ocorrência não natural (fhbp), composição, e célula hospedeira de neisseria meningitidis geneticamente modificada
PL3831406T3 (pl) 2010-08-23 2024-09-09 Wyeth Llc Stabilne preparaty antygenów rLP2086 Neisseria meningitidis
RU2546873C2 (ru) 2010-09-10 2015-04-10 УАЙТ ЭлЭлСи Нелипидизированные варианты антигенов neisseria meningitidis orf2086
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
MY167723A (en) 2012-03-09 2018-09-21 Pfizer Neisseria meningitidis compositions and methods thereof
WO2013186753A1 (en) 2012-06-14 2013-12-19 Novartis Ag Vaccines for serogroup x meningococcus
HK1205138A1 (en) 2012-07-27 2015-12-11 Institut National De La Santé Et De La Recherche Médicale (Inserm) Cd147 as receptor for pilus-mediated adhesion of meningococci to vascular endothelia
EP4056198A3 (en) * 2012-09-18 2022-12-07 GlaxoSmithKline Biologicals SA Outer membrane vesicles
US9802987B2 (en) 2013-03-08 2017-10-31 Pfizer Inc. Immunogenic fusion polypeptides
US20160030544A1 (en) * 2013-03-14 2016-02-04 Isis Innovation Limited Immunogenic composition to neisseria
BR112016002150A2 (pt) 2013-08-02 2017-09-12 Children´S Hospital & Res Center At Oakland proteínas de ligação de fator h de ocorrência natural (fhbp) e métodos de uso das mesmas
EP4098276A1 (en) 2013-09-08 2022-12-07 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
AU2015222121B2 (en) 2014-02-28 2018-01-18 Glaxosmithkline Biologicals Sa Modified meningococcal fHbp polypeptides
EP3169357B1 (en) * 2014-07-17 2018-11-07 GlaxoSmithKline Biologicals S.A. Modified meningococcal fhbp polypeptides
US11707513B2 (en) 2014-07-17 2023-07-25 Glaxosmithkline Biologicals Sa Meningococcus vaccines
KR102761870B1 (ko) * 2014-07-23 2025-02-05 칠드런즈 하스피틀 앤드 리써치 센터 앳 오클랜드 인자 h 결합 단백질 변이체 및 이의 사용 방법
EP3229835A1 (en) 2014-12-09 2017-10-18 Sanofi Pasteur Compositions comprising n. meningitidis proteins
US10888611B2 (en) 2015-02-19 2021-01-12 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
GB201614687D0 (en) * 2016-08-31 2016-10-12 Univ Oxford Innovation Ltd fHbp scaffold
AU2017321863B2 (en) 2016-09-02 2024-07-11 Sanofi Vaccines US Inc. Neisseria meningitidis vaccine
EP3312192B1 (en) * 2016-10-24 2023-02-22 BiOMVis Srl Immunogenic compositions containing bacterial outer membrane vesicles
PE20191107A1 (es) 2017-01-31 2019-08-26 Pfizer Composiciones de neisseria meningitidis y metodos respectivos
EP3607967A1 (en) * 2018-08-09 2020-02-12 GlaxoSmithKline Biologicals S.A. Modified meningococcal fhbp polypeptides
WO2021059181A1 (en) 2019-09-27 2021-04-01 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
CA3211240A1 (en) 2021-02-19 2022-08-25 Sanofi Pasteur Inc. Meningococcal b recombinant vaccine
TW202423477A (zh) 2022-08-03 2024-06-16 美商賽諾菲巴斯德公司 針對腦膜炎奈瑟氏菌b的含佐劑免疫原性組成物
CN120241991B (zh) * 2025-06-05 2025-12-23 北京绿竹生物技术股份有限公司 一种新型的b群流脑外膜蛋白双功能载体

Family Cites Families (123)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4057685A (en) 1972-02-02 1977-11-08 Abbott Laboratories Chemically modified endotoxin immunizing agent
DE2848965A1 (de) 1978-11-11 1980-05-22 Behringwerke Ag Verfahren zur herstellung von membranproteinen aus neisseria meningitidis und diese enthaltende vaccine
AU545912B2 (en) 1980-03-10 1985-08-08 Cetus Corporation Cloned heterologous jive products in bacillies
ZA811368B (en) 1980-03-24 1982-04-28 Genentech Inc Bacterial polypedtide expression employing tryptophan promoter-operator
GR75411B (enExample) 1981-04-29 1984-07-16 Biogen Nv
US4551433A (en) 1981-05-18 1985-11-05 Genentech, Inc. Microbial hybrid promoters
US4356170A (en) 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
US4673574A (en) 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
US4459286A (en) 1983-01-31 1984-07-10 Merck & Co., Inc. Coupled H. influenzae type B vaccine
JPS59166086A (ja) 1983-03-09 1984-09-19 Teruhiko Beppu 新規な発現型プラスミドとそれらを用いて仔牛プロキモシン遺伝子を大腸菌内で発現させる方法
US4663160A (en) 1983-03-14 1987-05-05 Miles Laboratories, Inc. Vaccines for gram-negative bacteria
JPS59205983A (ja) 1983-04-28 1984-11-21 ジエネツクス・コ−ポレイシヨン 異種遺伝子を原核微生物で発現させる方法
US4663280A (en) 1983-05-19 1987-05-05 Public Health Research Institute Of The City Of New York Expression and secretion vectors and method of constructing vectors
US4761283A (en) 1983-07-05 1988-08-02 The University Of Rochester Immunogenic conjugates
US4689406A (en) 1983-08-10 1987-08-25 Amgen Enhancement of microbial expression of polypeptides
JPS6054685A (ja) 1983-09-02 1985-03-29 Suntory Ltd 改良発現ベクタ−およびその利用
EP0136907A3 (en) 1983-10-03 1986-12-30 Genentech, Inc. A xenogeneic expression control system, a method of using it, expression vectors containing it, cells transformed thereby and heterologous proteins produced therefrom
US5916588A (en) 1984-04-12 1999-06-29 The Liposome Company, Inc. Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use
US6090406A (en) 1984-04-12 2000-07-18 The Liposome Company, Inc. Potentiation of immune responses with liposomal adjuvants
US4882317A (en) 1984-05-10 1989-11-21 Merck & Co., Inc. Covalently-modified bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers and methods of preparing such polysaccharides and conjugataes and of confirming covalency
US4695624A (en) 1984-05-10 1987-09-22 Merck & Co., Inc. Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency
US4808700A (en) 1984-07-09 1989-02-28 Praxis Biologics, Inc. Immunogenic conjugates of non-toxic E. coli LT-B enterotoxin subunit and capsular polymers
US4738921A (en) 1984-09-27 1988-04-19 Eli Lilly And Company Derivative of the tryptophan operon for expression of fused gene products
US4745056A (en) 1984-10-23 1988-05-17 Biotechnica International, Inc. Streptomyces secretion vector
IT1187753B (it) 1985-07-05 1987-12-23 Sclavo Spa Coniugati glicoproteici ad attivita' immunogenica trivalente
US4865974A (en) 1985-09-20 1989-09-12 Cetus Corporation Bacterial methionine N-terminal peptidase
JPS63123383A (ja) 1986-11-11 1988-05-27 Mitsubishi Kasei Corp ハイブリツドプロモ−タ−、発現調節ｄｎａ配列および発現ベクタ−
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
JPH01125328A (ja) 1987-07-30 1989-05-17 Centro Natl De Biopreparados 髄膜炎菌ワクチン
NL8802046A (nl) 1988-08-18 1990-03-16 Gen Electric Polymeermengsel met polyester en alkaansulfonaat, daaruit gevormde voorwerpen.
NZ230423A (en) 1988-08-25 1993-08-26 Liposome Co Inc A dosage form comprising an antigen and a multilamellar liposome comprising dimyristolyphosphatidylcholine (dmpc) and cholesterol
DE3841091A1 (de) 1988-12-07 1990-06-13 Behringwerke Ag Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung
WO1990006696A2 (en) 1988-12-19 1990-06-28 Praxis Biologics, Inc. Meningococcal class 1 outer-membrane protein vaccine
EP0378881B1 (en) 1989-01-17 1993-06-09 ENIRICERCHE S.p.A. Synthetic peptides and their use as universal carriers for the preparation of immunogenic conjugates suitable for the development of synthetic vaccines
JPH0832638B2 (ja) 1989-05-25 1996-03-29 カイロン コーポレイション サブミクロン油滴乳剤を含んで成るアジュバント製剤
FI920131A0 (fi) 1989-07-14 1992-01-13 Praxis Biolog Inc Cytokin- och hormonbaerare foer konjugatvaccin.
IT1237764B (it) 1989-11-10 1993-06-17 Eniricerche Spa Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
DE69113564T2 (de) 1990-08-13 1996-05-30 American Cyanamid Co Faser-Hemagglutinin von Bordetella pertussis als Träger für konjugierten Impfstoff.
IT1262896B (it) 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
NZ253137A (en) 1992-06-25 1996-08-27 Smithkline Beecham Biolog Vaccine comprising antigen and/or antigenic composition, qs21 (quillaja saponaria molina extract) and 3 de-o-acylated monophosphoryl lipid a.
IL102687A (en) 1992-07-30 1997-06-10 Yeda Res & Dev Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them
NL9201716A (nl) 1992-10-02 1994-05-02 Nederlanden Staat Buitenmembraanvesikel dat voorzien is van een groep polypeptiden welke ten minste de immuunwerking van aan membraan gebonden buitenmembraaneiwitten (OMP's) hebben, werkwijze ter bereiding ervan alsmede een vaccin dat een dergelijk buitenmembraanvesikel omvat.
EP0689454B2 (en) 1993-03-23 2005-02-23 SMITHKLINE BEECHAM BIOLOGICALS s.a. Vaccine compositions containing 3-o deacylated monophosphoryl lipid a
DE69433341T2 (de) 1993-09-22 2004-04-15 Henry M. Jackson Foundation For The Advancement Of Military Medicine Verfahren zur aktivierung von löslichem kohlenhydraten durch verwendung von neuen cyanylierungsreagenzien, zur herstellung von immunogenischen konstrukten
GB9326174D0 (en) 1993-12-22 1994-02-23 Biocine Sclavo Mucosal adjuvant
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
IL117483A (en) 1995-03-17 2008-03-20 Bernard Brodeur MENINGITIDIS NEISSERIA shell protein is resistant to proteinase K.
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US6180111B1 (en) 1995-05-18 2001-01-30 University Of Maryland Vaccine delivery system
GB9513261D0 (en) 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
US6558677B2 (en) 1996-10-15 2003-05-06 Wendell D. Zollinger Vaccine against gram negative bacteria
AU753688B2 (en) 1997-03-10 2002-10-24 Ottawa Civic Loeb Research Institute Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US6818222B1 (en) 1997-03-21 2004-11-16 Chiron Corporation Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
GB9711964D0 (en) 1997-06-09 1997-08-06 Medical Res Council Live attenuated vaccines
GB9712347D0 (en) 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
GB9713156D0 (en) 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
JP2001514001A (ja) 1997-08-21 2001-09-11 オランダ国 グラム陰性粘膜細菌の新規突然変異株及びそのワクチンにおける応用
CA2302554C (en) 1997-09-05 2007-04-10 Smithkline Beecham Biologicals S.A. Oil in water emulsions containing saponins
EP1029052B1 (en) 1997-11-06 2010-08-04 Novartis Vaccines and Diagnostics S.r.l. Neisserial antigens
GB9725084D0 (en) 1997-11-28 1998-01-28 Medeva Europ Ltd Vaccine compositions
AU1979599A (en) 1998-01-14 1999-08-02 Chiron S.P.A. (neisseria meningitidis) antigens
WO1999040936A2 (en) 1998-02-12 1999-08-19 American Cyanamid Company Pneumococcal and meningococcal vaccines formulated with interleukin-12
US6303114B1 (en) 1998-03-05 2001-10-16 The Medical College Of Ohio IL-12 enhancement of immune responses to T-independent antigens
HUP0101619A3 (en) 1998-04-09 2003-11-28 Smithkline Beecham Biolog Adjuvant compositions
CN100379757C (zh) 1998-05-01 2008-04-09 希龙公司 脑膜炎奈瑟球菌抗原和组合物
US6562798B1 (en) 1998-06-05 2003-05-13 Dynavax Technologies Corp. Immunostimulatory oligonucleotides with modified bases and methods of use thereof
GB9817052D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
NZ509986A (en) 1998-08-19 2003-10-31 Baxter Healthcare S Immunogenic beta-propionamido-linked polysaccharide and oligosaccharide protein conjugates as vaccines
DE122007000087I1 (de) 1998-10-16 2008-03-27 Glaxosmithkline Biolog Sa Adjuvanzsysteme und impfstoffe
EP1123403A1 (en) 1998-10-22 2001-08-16 The University Of Montana OMP85 PROTEINS OF $i(NEISSERIA GONORRHOEAE) AND $i(NEISSERIA MENINGITIDIS), COMPOSITIONS CONTAINING SAME AND METHODS OF USE THEREOF
GB9823978D0 (en) 1998-11-02 1998-12-30 Microbiological Res Authority Multicomponent meningococcal vaccine
AU1626199A (en) 1998-12-04 2000-06-26 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The A vi-repa conjugate vaccine for immunization against salmonella typhi
KR100642044B1 (ko) 1999-03-19 2006-11-10 글락소스미스클라인 바이오로지칼즈 에스.에이. 백신
EP1165796A2 (en) 1999-04-09 2002-01-02 Techlab, Inc. Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines
GB9918319D0 (en) 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
PL355163A1 (en) 1999-09-24 2004-04-05 Smithkline Beecham Biologicals S.A. Use of combination of polyoxyethylene sorbitan ester and octoxynol as adjuvant and its use in vaccines
BR0014285A (pt) 1999-09-24 2002-05-21 Smithkline Beecham Biolog Adjuvantes compreendendo um éster ou éter de alquila de polioxietileno e pelo menos um tensoativo não-iÈnico
GB9925559D0 (en) 1999-10-28 1999-12-29 Smithkline Beecham Biolog Novel method
WO2001034642A2 (en) 1999-11-12 2001-05-17 University Of Iowa Research Foundation Control of neisserial membrane synthesis
JP3701826B2 (ja) 1999-11-12 2005-10-05 株式会社村上開明堂 有色防曇鏡
ATE460484T1 (de) 1999-11-29 2010-03-15 Novartis Vaccines & Diagnostic 85 kda antigen von neisseria
CA2871789C (en) 2000-01-17 2017-04-04 Novartis Vaccines And Diagnostics S.R.L. Outer membrane vesicle (omv) vaccine comprising n. meningitidis serogroup b outer membrane proteins
WO2001095935A1 (en) 2000-01-20 2001-12-20 Ottawa Health Research Institute Immunostimulatory nucleic acids for inducing a th2 immune response
EP1252182B1 (en) 2000-01-25 2012-06-20 The University Of Queensland PROTEINS COMPRISING CONSERVED REGIONS OF NEISSERIA MENINGITIDIS SURFACE ANTIGEN NhhA
ES2281409T3 (es) 2000-02-28 2007-10-01 Novartis Vaccines And Diagnostics S.R.L. Expresion heterologa de proteinas de neisseria.
GB0007432D0 (en) 2000-03-27 2000-05-17 Microbiological Res Authority Proteins for use as carriers in conjugate vaccines
NO20002828D0 (no) 2000-06-02 2000-06-02 Statens Inst For Folkehelse Proteinholdig vaksine mot Neisseria meningtidis serogruppe samt fremgangsmÕte ved fremstilling derav
JP5511117B2 (ja) 2000-07-27 2014-06-04 チルドレンズ ホスピタル アンド リサーチ センター アット オークランド 髄膜炎菌に起因する疾患に対する広域防御のためのワクチン
GB0103170D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
JP2004509970A (ja) 2000-09-26 2004-04-02 ハイブリドン・インコーポレイテッド 位置的化学変化による免疫刺激オリゴヌクレオチドアナログの免疫刺激活性の調節
US7939087B2 (en) 2000-10-27 2011-05-10 Novartis Vaccines And Diagnostics, Inc. Nucleic acids and proteins from Streptococcus groups A & B
GB0103171D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
GB0103169D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
AU2002309706A1 (en) 2001-05-11 2002-11-25 Aventis Pasteur, Inc. Novel meningitis conjugate vaccine
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
WO2003009869A1 (en) 2001-07-26 2003-02-06 Chiron Srl. Vaccines comprising aluminium adjuvants and histidine
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
AU2002347404A1 (en) 2001-09-14 2003-04-01 Cytos Biotechnology Ag In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles
DE60234375D1 (de) 2001-09-14 2009-12-24 Cytos Biotechnology Ag VERPACKUNG VON IMMUNSTIMULIERENDEM CpG IN VIRUSÄHNLICHEN PARTIKELN: HERSTELLUNGSVERFAHREN UND VERWENDUNG
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
WO2003035836A2 (en) 2001-10-24 2003-05-01 Hybridon Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends
GB0130123D0 (en) 2001-12-17 2002-02-06 Microbiological Res Agency Outer membrane vesicle vaccine and its preparation
WO2003080678A1 (en) 2002-03-26 2003-10-02 Chiron Srl Modified saccharides having improved stability in water
DE20321889U1 (de) 2002-08-02 2012-03-12 Glaxosmithkline Biologicals S.A. Impfstoffzusammensetzung
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
DK2353608T3 (da) 2002-10-11 2020-02-10 Novartis Vaccines And Diagnostics S R L Polypeptid-vacciner til bred beskyttelse mod hypervirulente meningokok-linjer
DK2279746T3 (da) 2002-11-15 2013-11-25 Novartis Vaccines & Diagnostic Overfladeproteiner i neisseria meningitidis
GB0227346D0 (en) * 2002-11-22 2002-12-31 Chiron Spa 741
KR20060019515A (ko) * 2003-04-16 2006-03-03 와이어쓰 홀딩스 코포레이션 수막구균 질환의 예방 및 치료용 신규 면역원성 조성물
GB0316560D0 (en) 2003-07-15 2003-08-20 Chiron Srl Vesicle filtration
GB0419408D0 (en) 2004-09-01 2004-10-06 Chiron Srl 741 chimeric polypeptides
SI2682126T1 (sl) 2005-01-27 2017-03-31 Children's Hospital & Research Center At Oakland Cepiva na osnovi veziklov, osnovanih na GNA1870, za širokospektralno zaščito proti boleznim, povzročenim z Neisserio meningitidisom
GB0524066D0 (en) * 2005-11-25 2006-01-04 Chiron Srl 741 ii
CA2656474A1 (en) * 2006-06-29 2008-01-03 Novartis Ag Polypeptides from neisseria meningitidis
WO2009104097A2 (en) * 2008-02-21 2009-08-27 Novartis Ag Meningococcal fhbp polypeptides
AU2009288095A1 (en) * 2008-09-03 2010-03-11 Children's Hospital & Research Center At Oakland Peptides presenting an epitope of a domain of factor H binding protein and methods of use
GB0819633D0 (en) * 2008-10-25 2008-12-03 Isis Innovation Composition

Similar Documents

Publication Publication Date Title
JP2014503172A5 (enExample)
RU2375374C2 (ru) Домены и эпитопы менингококкового белка nmb1870
RU2012149618A (ru) Менингококковые полипептиды fhbp
JP2015505309A5 (enExample)
JP2013502918A5 (enExample)
BE1022641B1 (fr) POLYPEPTIDES MENINGOCOCCIQUES fHbp MODIFIES
JP2017114874A (ja) 免疫原性組成物
JP2010512792A5 (enExample)
DE20321889U1 (de) Impfstoffzusammensetzung
CN106061995A (zh) Uspa2蛋白质构建体及其用途
CN104107425A (zh) 预防再激活的结核病tb疫苗
JP2011105777A (ja) タンパク質を使用する髄膜炎菌の血清群ｙに対する免疫
JP2017522319A5 (enExample)
JP2012516140A5 (enExample)
JP6434017B2 (ja) マイコプラズマ属菌種の感染を予防する組成物
JP2012521404A5 (enExample)
EP2145898A1 (en) Anti-amyloid immunogenic compositions, methods and uses
JP2013520487A5 (enExample)
JP2015521595A (ja) 血清群ｘ髄膜炎菌のためのワクチン
EP3818989A1 (en) Peptides and oligonucleotides for a sars-cov-2 vaccine
KR101652060B1 (ko) 재조합 닭 전염성 코라이자 백신 및 그 제조방법
HRP20140886T1 (hr) MUTANTI CyaA POLIPEPTIDI I POLIPEPTIDNI DERIVATI PRIKLADNI ZA DOPREMANJE IMUNOGENIÄŚNIH MOLEKULA U STANICU
JP2010535504A5 (enExample)
US8449891B2 (en) Recombinant flagellin protein and preparation and use thereof
CN104072590B (zh) 一种脑膜炎球菌抗原组合及其应用